FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup
Date issued
2012Journal title
JOURNAL OF RHEUMATOLOGY
Type of content
Artigo